NCT00655655 - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

September 15, 2009

Study Completion Date

January 11, 2018

Conditions

GastrinomaGlucagonomaInsulinomaMetastatic Gastrointestinal Carcinoid TumorMetastatic PheochromocytomaPancreatic Polypeptide TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaRecurrent MelanomaRecurrent Neuroendocrine Carcinoma of the SkinRecurrent Non-small Cell Lung CancerRecurrent PheochromocytomaRecurrent Renal Cell CancerSomatostatinomaStage III Neuroendocrine Carcinoma of the SkinStage IV MelanomaStage IV Non-small Cell Lung CancerStage IV Renal Cell CancerThyroid Gland Medullary CarcinomaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

everolimus

Given orally

DRUG

vatalanib

Given orally

OTHER

pharmacological study

Correlative study (Cohort IIA only)

OTHER

laboratory biomarker analysis

Correlative study (Cohorts IIA and IIB)

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Correlative study (Cohort IIA only)

PROCEDURE

ultrasound imaging

Correlative study (Cohorts IIA and IIB)

Trial Locations (1)

55905

Mayo Clinic, Rochester